Featured Research

from universities, journals, and other organizations

Biomarker test for rheumatoid arthritis proves effective in study

Date:
June 26, 2012
Source:
University of Alabama at Birmingham
Summary:
A simple blood test may help physicians track the progression of rheumatoid arthritis disease activity, say researchers. The international research team says that a blood test measuring 12 biomarkers for RA is a valid and potentially useful tool in managing the disease.

A simple blood test may help physicians track the progression of rheumatoid arthritis disease activity, say researchers at the University of Alabama at Birmingham. In a paper published online on June 26, 2012, in Arthritis Care and Research, the UAB-led international research team says that a blood test measuring 12 biomarkers for RA is a valid and potentially useful tool in managing the disease.

"Previously, the disease activity of RA was assessed through clinical observation by a physician, noting the number of tender and swollen joints and assessing pain and functional abilities," said Jeffrey Curtis, M.D., associate professor in the division of clinical immunology and rheumatology and lead author of the study. "This blood test measures the underlying amount of RA activity within the joints using sophisticated biochemical means intended to reflect the underlying pathophysiology of the disease. A highly reproducible, easily standardized blood test that measures multiple biologic pathways to augment a physician's and patient's clinical assessment has not been previously available to physicians."

Curtis says the test emphasizes the activity of underlying biological pathways rather than external signs and symptoms and should therefore provide information that is different from, and complementary to, clinical assessment. He suggests the test may also help assess treatment response in patients. The test could show in just a few weeks whether a particular therapy is effective, rather than within three to four months as in current practice.

The blood test, called Vectra DA, is a multi-biomarker disease activity, or MBDA, test, developed by Crescendo Bioscienceฎ of South San Francisco. It is basically a measure of inflammation, looking for the presence of 12 cytokines, which are biomarkers, or biological red flags that can indicate the presence of disease.

Curtis says previous studies had selected the 12 biomarkers used in the MBDA from a list of 396 candidates and determined an algorithm that weighted the significance of each biomarker and produced a composite score. The new MBDA score correlated significantly with the DAS28-CRP score, a commonly-used composite metric used in clinical trials of RA treatments that assesses swollen joints, tender joints and the presence of a protein associated with inflammation.

"The MBDA score is a complementary tool that could provide physicians with an objective, consistent and biologically rich measure of RA disease activity," said Curtis.

Curtis says there are indications that the test could also prove valuable as a predictor of potential disease flare-ups, and also as a predictor of future joint damage, although those potential applications have yet to be demonstrated.

Researchers examined 512 patients drawn from three registries of patients with RA. Patients were diverse in terms of geographic location and disease characteristics.

Collaborators on the study include researchers from Leiden University Medical Center, Leiden, Netherlands; Crescendo Bioscience; Oklahoma Medical Research Foundation; Brigham and Women's Hospital, Boston; Rheumatology Associates of Long Island, NY; University of Texas Southwestern Medical Center, Dallas; and Mount Sinai Hospital, University of Toronto.

Curtis reports that he receives research support from the National Institutes of Health, the Agency for Healthcare Research and Quality and various pharmaceutical companies. He has also served as a consultant for Crescendo Bioscience.


Story Source:

The above story is based on materials provided by University of Alabama at Birmingham. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jeffrey R. Curtis, Annette H. van der Helm-van Mil, Rachel Knevel, Tom W. Huizinga, Douglas J. Haney, Yijing Shen, Saroja Ramanujan, Guy Cavet, Michael Centola, Lyndal K. Hesterberg, David Chernoff, Kerri Ford, Nancy A. Shadick, Max Hamburger, Roy Fleischmann, Edward Keystone and Michael E. Weinblatt. Validation of a novel multi-biomarker test to assess rheumatoid arthritis disease activity. Arthritis Care and Research, 2012; DOI: 10.1002/acr.21767

Cite This Page:

University of Alabama at Birmingham. "Biomarker test for rheumatoid arthritis proves effective in study." ScienceDaily. ScienceDaily, 26 June 2012. <www.sciencedaily.com/releases/2012/06/120626121039.htm>.
University of Alabama at Birmingham. (2012, June 26). Biomarker test for rheumatoid arthritis proves effective in study. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/06/120626121039.htm
University of Alabama at Birmingham. "Biomarker test for rheumatoid arthritis proves effective in study." ScienceDaily. www.sciencedaily.com/releases/2012/06/120626121039.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins